Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1299833

Cover Image

PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1299833

Vaccine Sales Market Report 2023-2033

PUBLISHED:
PAGES: 364 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Unprintable PDF (Single User) - 1 Year License
USD 4977
PDF (Team License - Up to 6 Users) - 1 Year License
USD 5670
PDF (Site License)
USD 6930
PDF (Enterprise License - Includes Free Datasets)
USD 8757

Add to Cart

The global Vaccine Sales market is projected to grow at a CAGR of 2.9% by 2033.

“The Vaccine Sales Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Investment in the Development of Vaccines to Boost Industry Growth

The growing attention towards vaccine research is attributed to the significant advancements in the domains of microbial pathogenesis and immunology. These developments have facilitated researchers and developers in devising preventive and therapeutic vaccines, as well as targeting novel diseases that were previously deemed unfeasible. Apart from the scientific progress, the current expansion of the worldwide vaccine market and the potential to attain "blockbuster" status by generating substantial sales revenue have motivated vaccine producers to revitalise and/or broaden their research endeavours. This is aimed at enhancing the public health impact while also achieving commercial success.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the vaccine sales market evolving?
  • What is driving and restraining the vaccine sales market?
  • How will each vaccine sales submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each vaccine sales submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading vaccine sales markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the vaccine sales projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of

vaccine sales projects taking place now and over the next 10 years?

  • Is there a greater need for product commercialisation to further scale the vaccine sales market?
  • Where is the vaccine sales market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the vaccine sales market today, and over the next 10 years:

  • Our 364-page report provides 140 tables and 199 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the vaccine sales market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Type

  • Inactivated
  • Live Attenuated
  • Toxoid
  • Recombinant/Conjugate/Subunit

Application

  • Pneumococcal
  • Influenza
  • Hepatitis
  • Meningococcal
  • COVID-19
  • Others

Route of Administration

  • Intramuscular
  • Subcutaneous
  • Oral

Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Age Group

  • Paediatrics
  • Adults

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South-East Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Vaccine Sales Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • AstraZeneca
  • Bavarian Nordic
  • Bharat Biotech
  • CSL
  • Daiichi Sankyo, Inc
  • Emergent BioSolutions Inc
  • GSK plc
  • INOVIO Pharmaceuticals
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc
  • Novavax
  • Panacea Biotec
  • Pfizer Inc
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Sinopharm
  • SINOVAC
  • Takeda Pharmaceutical Company Limited

Overall world revenue for Vaccine Sales Market, 2023 to 2033 in terms of value the market will surpass US$120 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Vaccine Sales Market, 2023 to 2033 report help you?

In summary, our 360+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Vaccine Sales Market, 2023 to 2033 Market, with forecasts for type, application, route of administration, distribution channel, and age group, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 22 key national markets - See forecasts for the Vaccine Sales Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Vaccine Sales Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Vaccine Sales Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Product Code: PHA1259

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Vaccine Sales Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Rising Focus and Government Support on Immunization Programs
      • 3.2.1.2 Growing Investment in Vaccine Development
      • 3.2.1.3 Increasing Company Initiatives to Enhance Vaccine R&D
      • 3.2.1.4 High Prevalence of Infectious Diseases
      • 3.2.1.5 Technological Advancements in Vaccine Administration
      • 3.2.1.6 Rapid Need of Immunization
      • 3.2.1.7 Strong Supply Backed Up by Robust R&D to Drive the Market
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Inadequate Reimbursement Coverage
      • 3.2.2.2 High Cost of Vaccine Development
      • 3.2.2.3 Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
      • 3.2.2.4 Stringent Government Regulations for Approval
      • 3.2.2.5 Inadequate Access to Vaccines
      • 3.2.2.6 Product Recalls
    • 3.2.3 Market Opportunities
      • 3.2.3.1 High Growth Prospects in Emerging Markets
      • 3.2.3.2 Focus on Therapeutic Vaccines
      • 3.2.3.3 Use of Adjuvants in Vaccines
      • 3.2.3.4 Government Support for Future Vaccine R&D
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Supplier
    • 3.4.2 Bargaining Power of Buyer
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat of New Entrants
    • 3.4.5 Threat of Substitutes
  • 3.5 PEST Analysis

4 Vaccine Sales Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Vaccine Sales Market Size Estimation and Forecast by Type
  • 4.4 Inactivated
    • 4.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Live Attenuated
    • 4.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 4.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.6 Toxoid
    • 4.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 4.6.2 Market Share by Region, 2023 & 2033 (%)
  • 4.7 Recombinant/Conjugate/Subunit
    • 4.7.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 4.7.2 Market Share by Region, 2023 & 2033 (%)

5 Vaccine Sales Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Vaccine Sales Market Size Estimation and Forecast by Application
  • 5.4 Pneumococcal
    • 5.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Influenza
    • 5.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 5.6 Hepatitis
    • 5.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 5.6.2 Market Share by Region, 2023 & 2033 (%)
  • 5.7 Meningococcal
    • 5.7.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 5.7.2 Market Share by Region, 2023 & 2033 (%)
  • 5.8 COVID-19
    • 5.8.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 5.8.2 Market Share by Region, 2023 & 2033 (%)
  • 5.9 Others
    • 5.9.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 5.9.2 Market Share by Region, 2023 & 2033 (%)

6 Vaccine Sales Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Vaccine Sales Market Size Estimation and Forecast by Route of Administration
  • 6.4 Intramuscular
    • 6.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Subcutaneous
    • 6.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Oral
    • 6.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Vaccine Sales Market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
  • 7.4 Hospital & Retail Pharmacies
    • 7.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 7.4.2 Market Share by Region, 2023 & 2033 (%)
  • 7.5 Government Suppliers
    • 7.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 7.5.2 Market Share by Region, 2023 & 2033 (%)
  • 7.6 Others
    • 7.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 7.6.2 Market Share by Region, 2023 & 2033 (%)

8 Vaccine Sales Market Analysis by Age Group

  • 8.1 Key Findings
  • 8.2 Age Group Segment: Market Attractiveness Index
  • 8.3 Vaccine Sales Market Size Estimation and Forecast by Age Group
  • 8.4 Paediatrics
    • 8.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 8.4.2 Market Share by Region, 2023 & 2033 (%)
  • 8.5 Adults
    • 8.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
    • 8.5.2 Market Share by Region, 2023 & 2033 (%)

9 Vaccine Sales Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Vaccine Sales Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Vaccine Sales Market Attractiveness Index
  • 10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
  • 10.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
  • 10.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
  • 10.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
  • 10.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
  • 10.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
  • 10.10 U.S. Vaccine Sales Market Analysis
  • 10.11 Canada Vaccine Sales Market Analysis

11 Europe Vaccine Sales Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Vaccine Sales Market Attractiveness Index
  • 11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
  • 11.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
  • 11.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
  • 11.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
  • 11.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
  • 11.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
  • 11.10 Germany Vaccine Sales Market Analysis
  • 11.11 UK Vaccine Sales Market Analysis
  • 11.12 France Vaccine Sales Market Analysis
  • 11.13 Italy Vaccine Sales Market Analysis
  • 11.14 Spain Vaccine Sales Market Analysis
  • 11.15 Russia Vaccine Sales Market Analysis
  • 11.16 Rest of Europe Vaccine Sales Market Analysis

12 Asia Pacific Vaccine Sales Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Vaccine Sales Market Attractiveness Index
  • 12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
  • 12.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
  • 12.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
  • 12.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
  • 12.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
  • 12.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
  • 12.10 Japan Vaccine Sales Market Analysis
  • 12.11 China Vaccine Sales Market Analysis
  • 12.12 India Vaccine Sales Market Analysis
  • 12.13 Australia Vaccine Sales Market Analysis
  • 12.14 South Korea Vaccine Sales Market Analysis
  • 12.15 South-East Asia Vaccine Sales Market Analysis
  • 12.16 Rest of Asia Pacific Vaccine Sales Market Analysis

13 Latin America Vaccine Sales Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Vaccine Sales Market Attractiveness Index
  • 13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
  • 13.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
  • 13.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
  • 13.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
  • 13.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
  • 13.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
  • 13.10 Brazil Vaccine Sales Market Analysis
  • 13.11 Mexico Vaccine Sales Market Analysis
  • 13.12 Rest of Latin America Vaccine Sales Market Analysis

14 MEA Vaccine Sales Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Vaccine Sales Market Attractiveness Index
  • 14.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 14.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
  • 14.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
  • 14.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
  • 14.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
  • 14.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
  • 14.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
  • 14.10 GCC Vaccine Sales Market Analysis
  • 14.11 South Africa Vaccine Sales Market Analysis
  • 14.12 Rest of MEA Vaccine Sales Market Analysis

15 Company Profiles

  • 15.1 Bavarian Nordic
    • 15.1.1 Company Snapshot
    • 15.1.2 Company Overview
    • 15.1.3 Financial Analysis
      • 15.1.3.1 Net Revenue, 2015-2022
      • 15.1.3.2 R&D, 2015-2022
      • 15.1.3.3 Regional Market Shares, 2022
    • 15.1.4 Product Benchmarking
    • 15.1.5 Strategic Outlook
  • 15.2 Bharat Biotech
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Product Benchmarking
    • 15.2.4 Strategic Outlook
  • 15.3 CSL
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2015-2022
      • 15.3.3.2 R&D, 2015-2022
      • 15.3.3.3 Regional Market Shares, 2022
    • 15.3.4 Product Benchmarking
    • 15.3.5 Strategic Outlook
  • 15.4 Emergent BioSolutions Inc.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2015-2022
      • 15.4.3.2 R&D, 2015-2022
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 GSK plc
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2015-2022
      • 15.5.3.2 R&D, 2015-2022
      • 15.5.3.3 Regional Market Shares, 2022
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
  • 15.6 INOVIO Pharmaceuticals
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2015-2022
      • 15.6.3.2 R&D, 2015-2022
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 Johnson & Johnson Services, Inc.
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2015-2022
      • 15.7.3.2 R&D, 2015-2022
      • 15.7.3.3 Regional Market Shares, 2022
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 Merck Co., Inc.
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2015-2022
      • 15.8.3.2 R&D, 2015-2022
      • 15.8.3.3 Regional Market Shares, 2022
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 Mitsubishi Tanabe Pharma Corporation
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Strategic Outlook
  • 15.10 Moderna, Inc.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2015-2022
      • 15.10.3.2 R&D, 2015-2022
    • 15.10.4 Product Benchmarking
    • 15.10.5 Strategic Outlook
  • 15.11 Novavax
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2015-2022
      • 15.11.3.2 R&D, 2015-2022
      • 15.11.3.3 Regional Market Shares, 2022
    • 15.11.4 Product Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 Panacea Biotec
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Product Benchmarking
  • 15.13 Pfizer Inc.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2015-2022
      • 15.13.3.2 R&D, 2015-2022
    • 15.13.4 Product Benchmarking
    • 15.13.5 Strategic Outlook
  • 15.14 Sanofi
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 Net Revenue, 2015-2022
      • 15.14.3.2 R&D, 2015-2022
      • 15.14.3.3 Regional Market Shares, 2022
    • 15.14.4 Product Benchmarking
    • 15.14.5 Strategic Outlook
  • 15.15 Serum Institute of India Pvt. Ltd.
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Product Benchmarking
    • 15.15.4 Strategic Outlook
  • 15.16 AstraZeneca
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Financial Analysis
      • 15.16.3.1 Net Revenue, 2015-2022
      • 15.16.3.2 R&D, 2015-2022
      • 15.16.3.3 Regional Market Shares, 2022
    • 15.16.4 Product Benchmarking
    • 15.16.5 Strategic Outlook
  • 15.17 Sinopharm
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Product Benchmarking
  • 15.18 SINOVAC
    • 15.18.1 Company Snapshot
    • 15.18.2 Company Overview
    • 15.18.3 Financial Analysis
      • 15.18.3.1 Net Revenue, 2015-2022
      • 15.18.3.2 R&D, 2015-2022
    • 15.18.4 Product Benchmarking
    • 15.18.5 Strategic Outlook
  • 15.19 Takeda Pharmaceutical Company Limited
    • 15.19.1 Company Snapshot
    • 15.19.2 Company Overview
    • 15.19.3 Financial Analysis
      • 15.19.3.1 Net Revenue, 2015-2022
      • 15.19.3.2 R&D, 2015-2022
      • 15.19.3.3 Regional Market Shares, 2022
    • 15.19.4 Product Benchmarking
    • 15.19.5 Strategic Outlook
  • 15.20 Daiichi Sankyo, Inc.
    • 15.20.1 Company Snapshot
    • 15.20.2 Company Overview
    • 15.20.3 Financial Analysis
      • 15.20.3.1 Net Revenue, 2015-2022
      • 15.20.3.2 R&D, 2015-2022
    • 15.20.4 Product Benchmarking
    • 15.20.5 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from
  • 16.2 Recommendations for Market Players
Product Code: PHA1259

List of Tables

  • Table 1: Vaccine Sales Market Snapshot, 2023 & 2033 (US$ Billion, CAGR %)
  • Table 2: Vaccine Cost Comparison: CDC Cost vs. Private Sector Cost (US$)
  • Table 3: Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
  • Table 4: Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
  • Table 5: Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
  • Table 6: Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
  • Table 7: Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 8: Inactivated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 9: Live Attenuated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 10: Toxoid Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 11: Recombinant/Conjugate/Subunit Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 12: Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 13: Pneumococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 14: Influenza Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 15: Hepatitis Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 16: Meningococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 17: COVID-19 Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 18: Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 19: Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 20: Intramuscular Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 21: Subcutaneous Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 22: Oral Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 23: Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 24: Hospital & Retail Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 25: Government Suppliers Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 26: Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 27: Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 28: Paediatrics Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 29: Adults Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 30: Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 31: North America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 32: North America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 33: North America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 34: North America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 35: North America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 36: North America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 37: U.S. Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 38: Canada Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 39: Europe Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 40: Europe Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 41: Europe Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 42: Europe Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 43: Europe Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 44: Europe Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 45: Germany Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 46: UK Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 47: France Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 48: Italy Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 49: Spain Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 50: Russia Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 51: Rest of Europe Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 52: Asia Pacific Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 53: Asia Pacific Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 54: Asia Pacific Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 55: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 56: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 57: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 58: Japan Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 59: China Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 60: India Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 61: Australia Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 62: South Korea Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 63: South-East Asia Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 64: Rest of Asia Pacific Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 65: Latin America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 66: Latin America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 67: Latin America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 68: Latin America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 69: Latin America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 70: Latin America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 71: Brazil Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 72: Mexico Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 73: Rest of Latin America Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 74: MEA Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 75: MEA Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 76: MEA Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 77: MEA Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 78: MEA Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 79: MEA Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
  • Table 80: GCC Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 81: South Africa Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 82: Rest of MEA Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
  • Table 83: Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84: Bavarian Nordic: Product Benchmarking
  • Table 85: Bavarian Nordic: Strategic Outlook
  • Table 86: Bharat Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 87: Bharat Biotech: Product Benchmarking
  • Table 88: Bharat Biotech: Strategic Outlook
  • Table 89: CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90: CSL: Product Benchmarking
  • Table 91: CSL: Strategic Outlook
  • Table 92: Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93: Emergent BioSolutions Inc.: Product Benchmarking
  • Table 94: Emergent BioSolutions Inc.: Strategic Outlook
  • Table 95: GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96: GSK plc: Product Benchmarking
  • Table 97: GSK plc: Strategic Outlook
  • Table 98: INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99: INOVIO Pharmaceuticals: Product Benchmarking
  • Table 100: INOVIO Pharmaceuticals: Strategic Outlook
  • Table 101: Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102: Johnson & Johnson Services, Inc.: Product Benchmarking
  • Table 103: Johnson & Johnson Services, Inc.: Strategic Outlook
  • Table 104: Merck Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105: Merck Co., Inc.: Product Benchmarking
  • Table 106: Merck Co., Inc.: Strategic Outlook
  • Table 107: Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108: Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
  • Table 109: Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
  • Table 110: Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111: Moderna, Inc.: Product Benchmarking
  • Table 112: Moderna, Inc.: Strategic Outlook
  • Table 113: Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 114: Novavax: Product Benchmarking
  • Table 115: Novavax: Strategic Outlook
  • Table 116: Panacea Biotec.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117: Panacea Biotec: Product Benchmarking
  • Table 118: Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 119: Pfizer Inc.: Product Benchmarking
  • Table 120: Pfizer Inc.: Strategic Outlook
  • Table 121: Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122: Sanofi: Product Benchmarking
  • Table 123: Sanofi: Strategic Outlook
  • Table 124: Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125: Serum Institute of India Pvt. Ltd.: Product Benchmarking
  • Table 126: Serum Institute of India Pvt. Ltd.: Strategic Outlook
  • Table 127: AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 128: AstraZeneca: Product Benchmarking
  • Table 129: AstraZeneca: Strategic Outlook
  • Table 130: Sinopharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131: Sinopharm: Product Benchmarking
  • Table 132: SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133: SINOVAC: Product Benchmarking
  • Table 134: SINOVAC: Strategic Outlook
  • Table 135: Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 136: Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 137: Takeda Pharmaceutical Company Limited: Strategic Outlook
  • Table 138: Daiichi Sankyo, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 139: Daiichi Sankyo, Inc.: Product Benchmarking
  • Table 140: Daiichi Sankyo, Inc.: Strategic Outlook

List of Figures

  • Figure 1: Vaccine Sales Market Segmentation
  • Figure 2: Vaccine Sales Market by Type: Market Attractiveness Index
  • Figure 3: Vaccine Sales Market by Application: Market Attractiveness Index
  • Figure 4: Vaccine Sales Market by Route of Administration: Market Attractiveness Index
  • Figure 5: Vaccines market by distribution channel: Market Attractiveness Index
  • Figure 6: Vaccine Sales Market by Age Group: Market Attractiveness Index
  • Figure 7: Vaccine Sales Market Attractiveness Index by Region
  • Figure 8: Vaccine Sales Market: Market Dynamics
  • Figure 9: Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): "V" Shaped Recovery
  • Figure 10: Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): "U" Shaped Recovery
  • Figure 11: Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): "W" Shaped Recovery
  • Figure 12: Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): "L" Shaped Recovery
  • Figure 13: Vaccine Sales Market: Porter's Five Forces Analysis
  • Figure 14: Vaccine Sales Market: PEST Analysis
  • Figure 15: Vaccine Sales Market Attractiveness Index by Type
  • Figure 16: Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
  • Figure 17: Vaccine Sales Market Share Forecast by Type, 2023, 2028, 2033 (%)
  • Figure 18: Inactivated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 19: Inactivated Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 20: Live Attenuated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 21: Live Attenuated Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 22: Toxoid Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 23: Toxoid Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 24: Recombinant/Conjugate/Subunit Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 25: Recombinant/Conjugate/Subunit Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 26: Vaccine Sales Market Attractiveness Index by Type
  • Figure 27: Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
  • Figure 28: Vaccine Sales Market Share Forecast by Application, 2023, 2028, 2033 (%)
  • Figure 29: Pneumococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 30: Pneumococcal Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 31: Influenza Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 32: Influenza Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 33: Hepatitis Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 34: Hepatitis Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 35: Meningococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 36: Meningococcal Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 37: COVID-19 Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 38: COVID-19 Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 39: Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 40: Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 41: Vaccine Sales Market Attractiveness Index by Route of Administration
  • Figure 42: Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
  • Figure 43: Vaccine Sales Market Share Forecast by Route of Administration, 2023, 2028, 2033 (%)
  • Figure 44: Intramuscular Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 45: Intramuscular Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 46: Subcutaneous Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 47: Subcutaneous Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 48: Oral Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 49: Oral Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 50: Vaccine Sales Market Attractiveness Index by Distribution Channel
  • Figure 51: Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
  • Figure 52: Vaccine Sales Market Share Forecast by Distribution Channel, 2023, 2028, 2033 (%)
  • Figure 53: Hospital & Retail Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 54: Hospital & Retail Pharmacies Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 55: Government Suppliers Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 56: Government Suppliers Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 57: Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 58: Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 59: Vaccine Sales Market Attractiveness Index by Age Group
  • Figure 60: Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
  • Figure 61: Vaccine Sales Market Share Forecast by Age Group, 2023, 2028, 2033 (%)
  • Figure 62: Paediatrics Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 63: Paediatrics Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 64: Adults Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
  • Figure 65: Adults Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 66: Vaccine Sales Market Forecast by Region 2023 & 2033 (Revenue, CAGR%)
  • Figure 67: Vaccine Sales Market Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 68: Vaccine Sales Market by Region, 2023-2033 (US$ Bn)
  • Figure 69: North America Vaccine Sales Market Attractiveness Index
  • Figure 70: North America Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
  • Figure 71: North America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
  • Figure 72: North America Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 73: North America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
  • Figure 74: North America Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 75: North America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
  • Figure 76: North America Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 77: North America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
  • Figure 78: North America Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 79: North America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
  • Figure 80: North America Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
  • Figure 81: North America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
  • Figure 82: North America Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
  • Figure 83: U.S. Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 84: Canada Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 85: Europe Vaccine Sales Market Attractiveness Index
  • Figure 86: Europe Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
  • Figure 87: Europe Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
  • Figure 88: Europe Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 89: Europe Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
  • Figure 90: Europe Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 91: Europe Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
  • Figure 92: Europe Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 93: Europe Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
  • Figure 94: Europe Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 95: Europe Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
  • Figure 96: Europe Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
  • Figure 97: Europe Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
  • Figure 98: Europe Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
  • Figure 99: Germany Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 100: UK Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 101: France Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 102: Italy Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 103: Spain Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 104: Russia Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 105: Rest of Europe Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 106: Asia Pacific Vaccine Sales Market Attractiveness Index
  • Figure 107: Asia Pacific Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
  • Figure 108: Asia Pacific Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
  • Figure 109: Asia Pacific Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 110: Asia Pacific Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
  • Figure 111: Asia Pacific Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 112: Asia Pacific Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
  • Figure 113: Asia Pacific Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 114: Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
  • Figure 115: Asia Pacific Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 116: Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
  • Figure 117: Asia Pacific Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
  • Figure 118: Asia Pacific Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
  • Figure 119: Asia Pacific Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
  • Figure 120: Japan Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 121: China Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 122: India Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 123: Australia Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 124: South Korea Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 125: South-East Asia Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 126: Rest of Asia Pacific Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 127: Latin America Vaccine Sales Market Attractiveness Index
  • Figure 128: Latin America Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
  • Figure 129: Latin America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
  • Figure 130: Latin America Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 131: Latin America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
  • Figure 132: Latin America Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 133: Latin America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
  • Figure 134: Latin America Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 135: Latin America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
  • Figure 136: Latin America Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 137: Latin America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
  • Figure 138: Latin America Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
  • Figure 139: Latin America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
  • Figure 140: Latin America Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
  • Figure 141: Brazil Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 142: Mexico Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 143: Rest of Latin America Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 144: MEA Vaccine Sales Market Attractiveness Index
  • Figure 145: MEA Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
  • Figure 146: MEA Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
  • Figure 147: MEA Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 148: MEA Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
  • Figure 149: MEA Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 150: MEA Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
  • Figure 151: MEA Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 152: MEA Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
  • Figure 153: MEA Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 154: MEA Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
  • Figure 155: MEA Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
  • Figure 156: MEA Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
  • Figure 157: MEA Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
  • Figure 158: GCC Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 159: South Africa Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 160: Rest of MEA Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
  • Figure 161: Bavarian Nordic: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 162: Bavarian Nordic: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 163: Bavarian Nordic: Regional Market Shares, 2022
  • Figure 164: CSL: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 165: CSL: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 166: CSL: Regional Market Shares, 2022
  • Figure 167: Emergent BioSolutions Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 168: Emergent BioSolutions Inc.: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 169: GSK plc: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 170: GSK plc: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 171: GSK plc: Regional Market Shares, 2022
  • Figure 172: INOVIO Pharmaceuticals: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 173: INOVIO Pharmaceuticals: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 174: Johnson & Johnson Services, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 175: Johnson & Johnson Services, Inc.: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 176: Johnson & Johnson Services, Inc.: Regional Market Shares, 2022
  • Figure 177: Merck Co., Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 178: Merck Co., Inc.: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 179: Merck Co., Inc.: Regional Market Shares, 2022
  • Figure 180: Moderna, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 181: Moderna, Inc.: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 182: Novavax: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 183: Novavax: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 184: Novavax: Regional Market Shares, 2022
  • Figure 185: Pfizer Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 186: Pfizer Inc.: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 187: Sanofi: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 188: Sanofi: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 189: Sanofi: Regional Market Shares, 2022
  • Figure 190: AstraZeneca: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 191: AstraZeneca: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 192: AstraZeneca: Regional Market Shares, 2022
  • Figure 193: SINOVAC: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 194: SINOVAC: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 195: Takeda Pharmaceutical Company Limited: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 196: Takeda Pharmaceutical Company Limited: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 197: Takeda Pharmaceutical Company Limited: Regional Market Shares, 2022
  • Figure 198: Daiichi Sankyo, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 199: Daiichi Sankyo, Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!